Bank of America’s Avenue Therapeutics, Inc. Common Stock ATXI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-14
| Closed | -$28 | – | 8661 |
|
|
2024
Q4 | $28 | Buy |
14
+4
| +40% | +$8 | ﹤0.01% | 7971 |
|
|
2024
Q3 | $25 | Buy |
10
+3
| +43% | +$9 | ﹤0.01% | 7940 |
|
|
2024
Q2 | $24 | Buy |
+7
| New | +$41 | ﹤0.01% | 7972 |
|
|
2023
Q1 | – | Hold |
0
| – | -$14 | – | 8365 |
|
|
2022
Q4 | – | Hold |
0
| – | – | – | 8039 |
|
|
2022
Q3 | – | Hold |
0
| – | – | – | 8270 |
|
|
2022
Q2 | – | Hold |
0
| – | – | – | 8479 |
|
|
2022
Q1 | – | Hold |
0
| – | – | – | 8875 |
|
|
2021
Q4 | – | Hold |
0
| – | – | – | 8738 |
|
|
2021
Q3 | – | Sell |
-2
| Closed | -$4.13K | – | 8459 |
|
|
2021
Q2 | $4K | Sell |
2
-7
| -78% | -$34.5K | ﹤0.01% | 7471 |
|
|
2021
Q1 | $63K | Buy |
9
+6
| +200% | +$41.2K | ﹤0.01% | 6556 |
|
|
2020
Q4 | $18K | Buy |
3
+1
| +50% | +$5.24K | ﹤0.01% | 6615 |
|
|
2020
Q3 | $19K | Hold |
2
| – | – | ﹤0.01% | 6301 |
|
|
2020
Q2 | $29K | Sell |
2
-4
| -67% | -$45.1K | ﹤0.01% | 6170 |
|
|
2020
Q1 | $63K | Buy |
+6
| New | +$60.1K | ﹤0.01% | 5772 |
|
|
2019
Q4 | – | Hold |
0
| – | – | – | 7479 |
|
|
2019
Q3 | – | Hold |
0
| – | – | – | 7566 |
|
|
2019
Q2 | – | Hold |
0
| – | -$1K | – | 7460 |
|
|
2019
Q1 | – | Hold |
0
| – | – | – | 7010 |
|
|
2018
Q4 | – | Sell |
-1
| Closed | -$2K | – | 7442 |
|
|
2018
Q3 | $2K | Buy |
+1
| New | +$4.11K | ﹤0.01% | 7048 |
|
Bank of America's ATXI Position: Q1 2025 in Review
Bank of America sold out of Avenue Therapeutics, Inc. Common Stock (ATXI) in Q1 2025, closing a stake of 14 shares — an estimated $28 sold.
Bank of America first reported a position in ATXI in Q3 2018 and held it in 10 quarters. The position peaked at $63K in Q1 2021. 0 funds tracked by Wall St. Rank hold ATXI as of Q1 2025.
- Bank of America reported no remaining Avenue Therapeutics, Inc. Common Stock position as of Q1 2025 after selling out during the quarter.
- Bank of America sold 14 Avenue Therapeutics, Inc. Common Stock shares in Q1 2025, an estimated $28.
- Bank of America first reported a position in Avenue Therapeutics, Inc. Common Stock in Q3 2018 and held it in 10 quarters.
- Bank of America's Avenue Therapeutics, Inc. Common Stock position peaked at $63K in Q1 2021.
- 0 funds tracked by Wall St. Rank held Avenue Therapeutics, Inc. Common Stock as of Q1 2025.
Based on Bank of America's 13F filing for Q1 2025, filed 15 May 2025.